Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,213 GBX | -0.27% | -0.86% | +14.70% |
10:04am | ASTRAZENECA : UBS reiterates its Sell rating | ZD |
05-14 | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.70% | 239B | |
+31.18% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+10.25% | 210B | |
-6.87% | 200B | |
+8.12% | 167B | |
-1.42% | 161B | |
+1.50% | 124B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- AstraZeneca's Breast Cancer Drug Improves Progression-free Survival in Late-stage Study